Table 4.

Cox proportional hazard analysis for the primary and secondary outcomes (n = 2308).

(A) Death from any cause (event n = 809)	Hazard ratio (95% CI)	P value
Group C	Reference	–
Group M (unadjusted)	2.053 (1.568–2.688)	< 0.001
Group M (model 1)	2.287 (1.743–2.999)	< 0.001
Group M (model 2)	1.790 (1.141–2.810)	0.011
Group K (unadjusted)	2.451 (2.102–2.857)	< 0.001
Group K (model 1)	2.251 (1.928–2.628)	< 0.001
Group K (model 2)	1.657 (1.172–2.344)	0.004
Group MK (unadjusted)	4.112 (3.193–5.296)	< 0.001
Group MK (model 1)	3.718 (2.879–4.801)	< 0.001
Group MK (model 2)	2.313 (1.375–3.893)	0.002

(B) Cardiac death (event n = 362)	Hazard ratio (95% CI)	P value
Group C	Reference	–
Group M (unadjusted)	2.363 (1.622–3.443)	< 0.001
Group M (model 1)	2.627 (1.798–3.838)	< 0.001
Group M (model 2)	2.053 (1.074–3.922)	0.029
Group K (unadjusted)	2.236 (1.770–2.826)	< 0.001
Group K (model 1)	2.102 (1.661–2.661)	< 0.001
Group K (model 2)	1.855 (1.096–3.139)	0.021
Group MK (unadjusted)	4.282 (2.965–6.183)	< 0.001
Group MK (model 1)	4.030 (2.780–5.843)	< 0.001
Group MK (model 2)	3.001 (1.419–6.345)	0.004

CI, confidence interval.

Model 1: adjusted for age and sex.

Model 2: adjusted for age, sex, New York Heart Association class 3 or 4, left ventricular ejection fraction, systolic blood pressure, coronary artery disease, use of renin-angiotensin system inhibitors, beta blockers, mineralocorticoid receptor antagonists, statins, and antihyperuricemic agents, implantable cardioverter-defibrillator and/or cardiac resynchronization therapy, and levels of log-transformed B-type natriuretic peptide, estimated glomerular filtration rate, hemoglobin, lymphocytes, uric acid, total cholesterol, and sodium.

Age, left ventricular ejection fraction, systolic blood pressure, and levels of log-transformed B-type natriuretic peptide, estimated glomerular filtration rate, hemoglobin, lymphocytes, uric acid, total cholesterol, and sodium were analyzed as continuous variables.